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Background: The accumulation of misfolded proteins appears as a fundamental pathogenic process in human
neurodegenerative diseases. In the case of synucleinopathies such as Parkinson’s disease (PD) or dementia with
Lewy bodies (DLB), the intraneuronal deposition of aggregated alpha-synuclein (αS) is a major characteristic of the
disease, but the molecular basis distinguishing the disease-associated protein (αSD) from its normal counterpart
remains poorly understood. However, recent research suggests that a prion-like mechanism could be involved in
the inter-cellular and inter-molecular propagation of aggregation of the protein within the nervous system.
Results: Our data confirm our previous observations of disease acceleration in a transgenic mouse line (M83)
overexpressing a mutated (A53T) form of human αS, following inoculation of either brain extracts from sick M83
mice or fibrillar recombinant αS. A similar phenomenon is observed following a “second passage” in the M83
mouse model, including after stereotactic inoculations into the hippocampus or cerebellum. For further molecular
analyses of αSD, we designed an ELISA test that identifies αSD specifically in sick mice and in the brain regions
targeted by the pathological process in this mouse model. αSD distribution, mainly in the caudal brain regions and
spinal cord, overall appears remarkably uniform, whatever the conditions of experimental challenge. In addition to
specific detection of αSD immunoreactivity using an antibody against Ser129 phosphorylated αS, similar results
were observed in ELISA with several other antibodies against the C-terminal part of αS, including an antibody
against non phosphorylated αS. This also indicated consistent immunoreactivity of the murine αS protein specifically
in the affected brain regions of sick mice.
Conclusions: Prion-like behaviour in propagation of the disease-associated αS was confirmed with the M83
transgenic mouse model, that could be followed by an ELISA test. The ELISA data question their possible
relationship with the conformational differences between the disease-associated αS and its normal counterpart.
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Pathological accumulation of misfolded alpha-synuclein
(αS) plays a central role in the pathogenesis of synuclei-
nopathies, human neuro-degenerative diseases including
Parkinson’s Diseases (PD), dementia with Lewy bodies
(DLB), and multiple system atrophy (MSA) [1]. PD is
characterized by specific lesions in the brain, with Lewy* Correspondence: thierry.baron@anses.fr
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unless otherwise stated.bodies and Lewy neurites representing deposits of aggre-
gated αS. The crucial role of αS in PD was initially dis-
covered during studies of a few genetic cases of the
disease caused by point mutations of the SNCA gene
coding for αS, or by its duplication or triplication [2,3],
which in the latter case indicated that increased levels of
the protein were sufficient to cause the disease.
Considerable interest has recently been shown in the
hypothesis that αS aggregation could involve a prion-like
mechanism for its propagation, involving self-replication
and spreading of a misfolded β-sheet enriched pathogenical Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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was triggered by observations of Lewy bodies and neurites
in the embryonic mesencephalic neurons grafted in PD
patients’brains, when examined over 10 years following
the transplant procedure [6,7]. The stereotypical pattern
of lesion progression in PD patients had already been well
established by Braak who suggested that PD could be initi-
ated by environmental insults (toxins or pathogens) in the
enteric nervous system and/or olfactory bulb before
propagating to and within the central nervous system [8].
Recent experimental studies have strongly reinforced this
hypothesis and some studies involving in vitro models
suggest that αS aggregation can spread by axonal transport
into the neurons and by cell-to-cell transfer [9].
We previously reported the first in vivo experimental
evidence that a synucleinopathy could be accelerated by
inoculating brain extracts containing a disease-associated
αS form in a transgenic mouse model (M83) expressing
an A53T mutated human αS protein that is associated
with a severe motor impairment occurring during aging of
mice [5,10]. The idea that αS aggregation could be trig-
gered or accelerated by intra-cerebral inoculation of aggre-
gated αS was further confirmed in the same M83 mouse
model by inoculation with fibrillar recombinant αS or
brain extracts from human MSA patients, and also after
inoculation of C57Bl/6 wild-type mice with either fibrillar
recombinant αS or brain extracts from human DLB pa-
tients [4,11-13].
Results
We previously described the acceleration of a synuclei-
nopathy in a transgenic mouse model (line M83) ex-
pressing the A53T mutated human αS protein, when
mice were intra-cerebrally inoculated with brain extracts
prepared from sick old M83 mice [5]. At the stage of
clinical disease, these mice specifically showed accumu-
lation in the brain of insoluble pSer129 αS [5,14], with a
typical 4 band pattern detected by Western blot corre-
sponding to monomeric and oligomeric αS forms, ubi-
quitinated or not [4,12,15].
Development of an ELISA test for disease-associated
α-synuclein (αSD) detection
We have now developed an ELISA test that specifically
identifies the disease-associated αS (αSD) in brain ho-
mogenates prepared in High Salt buffer from sick M83
mice, without any concentration step, unlike Western blot
that requires ultracentrifugation in the presence of sarko-
syl to detect the protein (Additional file 1: Figure S1B)
[14]. Immunoreactivity readily distinguishes old and sick
(> 8 months old) from young and healthy (2–5 month
old) M83 mice (Figure 1A), using an antibody specifically
recognizing the pSer129 αS (p = 0.0074). However it is in-
teresting that several other antibodies showed similarlyhigh immunoreactivities in brain homogenates from sick
mice, including 4D6 (p = 0.01), LB509 (p = 0.0047), 8A5
(p < 0.001) against different sequences of the C-terminal
part of the protein (124–134, 115–122, and 129–140 re-
spectively) and, to a much lesser extent, Syn514 against
the N-terminal end (2–12) of the protein (p = 0.0003).
In contrast, under these experimental conditions, ana-
lysis with clone 42 reporter antibody, against a central
region of α-synuclein (91–96), did not allow to distin-
guish sick and healthy M83 mice (p = 0.1158). As with
other antibodies, a higher imunoreactivity was found in
young M83 mice, compared to non transgenic B6C3H
mice and still more importantly to B6 αS-null [16] mice,
consistently with Western blot analysis of crude brain
homogenates (Additional file 1: Figure S1C). As αSD has
never been detected in M83 mice younger than 4–
6 months [4,5,10,15,17], this likely represents detection
of normal human αS overexpressed in M83 mice, which
however remains limited under these ELISA conditions.
The sensitivity of this ELISA test for αSD detection
was compared to the previously described Western-blot
method [5], by using both tests to examine serial dilu-
tions from the same sick M83 mouse brain (Figure 1B).
Based on the results obtained during 3–6 repeats of ELISA
measures from samples of healthy M83 mice, the esti-
mated cut-off level for discrimination of sick and healthy
mice (means + 3 standard deviations) was 0.030 and 0.020
for LB509 and PSer129 antibodies respectively. Under
these conditions, a positive ELISA signal was obtained for
the brain homogenate from a sick mouse with ~ 10 μg
brain equivalents, with both LB509 and PSer129 anti-
bodies, whereas at least 200 μg brain equivalents were
necessary to detect pSer129 αS in the sarkosyl insoluble
fraction by Western blot with the same PSer129 anti-
body (Figure 1C).
Detection of αSD in M83 mice after inoculation of brain
extracts from sick mice
We then examined sick M83 mice that developed early
clinical signs following intra-cerebral inoculation of brain
extracts from sick M83 mice. This included mice that
became sick at an early age (~ 4–6 months old) when
inoculated with brain extracts from uninoculated M83
mice which had developed the disease during aging [10]
(“first passage”, P1) [14], and also from mice inoculated
with brain extracts from these “first passage” mice (“sec-
ond passage”, P2) (Table 1). The survival period after
this second passage was again strikingly reduced in
comparison to uninoculated mice, after the inoculation
of three different concentrations of brain homogenates
(5, 1 or 0.2%, i.e. corresponding to 10, 2 or 0.4 mg of
brain equivalents per mouse, respectively). Whereas
the mice survival periods did not differ significantly for
the two largest amounts of brain homogenates injected
Figure 1 Detection of disease-associated α-synuclein (αSD) in M83 mice homogenates from whole brain by ELISA. A. Anti α-syn antibodies
immunoreactivity was tested on 4 symptomatic M83 mice from 11 to 16 months old, in comparison with 6 asymptomatic mice from 2 to 5 months old.
B6C3H (genetic background of M83 mice) or B6 αS-null mice were used as additional controls. Sandwich ELISA with rabbit anti-αS polyclonal
(capture)/Syn514, LB509, 4D6, 8A5 (reporters) and with clone 42 (capture)/anti-pSer129 αS (PSer129) (reporter) antibodies allows sick mice to be
distinguished from asymptomatic M83 mice, whereas ELISA with anti-αS rabbit polyclonal (capture)/clone42 (reporter) does not. Error bars
represent S.D. B. Determination of the sensitivity of detection of αSD by ELISA. Two-fold dilutions of brain homogenates from a sick mouse were
tested, and a positive signal was obtained for 12.5 μg brain equivalents, with both LB509 and PSer129 antibodies. Cut-offs for LB509 and PSer129 were
visualized by a line in the color of the antibodies. C. Determination of the sensitivity of detection of αSD by Western blot. 200 μg brain equivalents were
necessary to detect αSD in Western blot with PSer129 antibody. Molecular weight markers (in kDa) are indicated on the left of the blot.
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cantly longer when smaller amounts (0.4 mg) of brain
homogenates (p = 0.0393) were injected (Figure 2A).
Survival periods had also been significantly longer in
the previous first passage experiment performed from
a 1% homogenate of an old uninoculated and sick mouse
(p = 0.0038) [5]. Importantly however, and in contrast with
uninoculated M83 mice, all mice receiving brain homoge-
nates that contained aggregated αS developed clinical dis-
ease before they were 8 months old.
ELISA analyses of brain homogenates using an anti-
body against pSer129 αS also clearly distinguished sick
inoculated and healthy uninoculated age-matched M83
mice (Figure 3A). No significant difference in immuno-
reactivity was observed between inoculated and uninoc-
ulated sick M83 mice (p = 0.77). However, as in aged
uninoculated mice, the levels of αSD in inoculated M83
mice were variable, and can be roughly divided into two
groups of either low (OD < 0.2) or high (OD 0.2 – 1)immunoreactivity. Similar results were obtained with the
two antibodies LB509 and PSer129, chosen for further
ELISA studies. These individual variations of ELISA im-
munoreactivities were also quite consistent with those
observed by Western blot analysis with the PSer129
antibody of the pellets obtained after ultra-centrifugation
from the same mouse brains (Figure 3B). The levels of
αSD detected were lower in all mice inoculated with the
highest amount of brain extract (10 mg), differing sig-
nificantly (p = 0.01) from the two other groups of mice
inoculated with 2 or 0.4 mg of brain equivalents. The
mice inoculated with 10 mg of brain tissue showed con-
comitantly lower αSD detection (Figure 3) and shorter
survivals (Figure 2A).
Neuro-anatomic distribution of αSD in sick M83 mice
In addition to using some mice from the previously de-
scribed experimental groups, we also performed exper-
iments (Table 1) including i) inoculation of fibrillar
Table 1 List of experiments performed on M83 mice
Experiment Passage Inoculum (brain equivalent





αSd detection by Western
blot or ELISA or IHC
1 P1 (2 mg) 129 +/− 19 192/217 8/8
2 αSrec fib (10 μg) 106 +/− 27 145/216 6/6
3 P2 (10 mg) 105 +/− 23 146/181 5/5
4 P2 (2 mg) 107 +/− 12 147/173 8/8
5 P2 (0.4 mg) 140 +/− 33 188/232 9/10
6 P2 Stx hippocampus (2 mg) 130 +/− 13 171/196 5/5
7 P2 Stx cerebellum (2 mg) 131 +/− 50 159/187 4/4
8 P2 spinal cord (2 mg) 113 +/− 22 163/174 5/5
9 P2 cerebral cortex (2 mg) 224 +/− 93 219/472 5/5
10 P2 spleen (2 mg) 378 +/− 98 374/584 4/5
Inoculations were performed at 6 weeks except for experiment 1 (9 weeks).
P1: passage 1, P2: passage 2, Stx: stereotactic, d.p.i.: days post inoculation.
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two second passage experiments during which brain
extracts from sick M83 mice (2 mg brain equivalents/
mouse) were stereotaxically inoculated in the hippo-
campus (experiment 6) or cerebellum (experiment 7).
The M83 mice also exhibited acceleration of the disease
with the characteristic motor clinical signs, both in mice
inoculated with recombinant fibrillar αS (Figure 2A) and
stereotaxically with brain extracts (Figure 2B). Survivals of
the animals after inoculations did not significantly differ
from that previously observed in the first passage experi-
ment by inoculation of a brain from an old and sick mouse
(experiment 1) (p = 0.0979, 0.852 and 0.8205 for experi-
ments 2, 6 and 7 respectively). There was no statistical dif-
ference between stereotactic inoculation to hippocampus
or cerebellum (p = 0.725).
Also, another second passage experiment using inocu-
lation of a spinal cord homogenate similarly showed an
acceleration of disease onset (Figure 2C) with the char-
acteristic motor clinical signs, comparable to that previ-
ously observed with whole brain homogenate, whereas
inoculation of a cerebral cortex homogenate from the
same mouse accelerated the disease to a lesser extent. No
reduction in survival time was observed in M83 mice in-
oculated with a spleen homogenate of this same mouse.
Survivals in these three experimental groups (experiments
8–10) significantly differ from each other (p < 0.05).
Western blot studies after brain dissection revealed
insoluble pSer129 αS mainly in the mesencephalon,
brain stem and spinal cord, and faintly in the cerebel-
lum (Figures 4A-D), as in uninoculated sick and old M83
mice (data not shown). The same bands were also recog-
nized by clone 42 and, to a lesser extent, LB509 antibodies
(Figures 4B-C). As shown for mice inoculated with brain
extracts from sick mice at first passage (Figure 4E), or with
fibrillar recombinant αS (Figure 4F), brain homogenates
from these brain regions (mesencephalon, brain stem andspinal cord) reacted strongly with both LB509 and
PSer129 antibodies in ELISA. Other brain regions in-
cluding the olfactory bulb, cerebral cortex, striatum,
hippocampus, thalamus and hypothalamus typically
did not show any detectable αSD by Western blot or
ELISA. A faint signal in the cerebellum was obtained
with both ELISA and Western blot.
The kinetic of αSD detection by ELISA was examined
by sacrificing M83 mice 8 or 12 weeks following their in-
oculation with brain homogenate from a sick M83 mouse
(“second passage”). Immunoreactivity was detected in the
mesencephalon, brain stem and spinal cord of mice sacri-
ficed at 12 weeks, but not in age-matched uninoculated
mice (Figure 5A) or in those sacrificed at 8 weeks (data
not shown).
We also examined the possible αSD detection of mouse
origin, in sick M83 mice using a mouse specific antibody,
D37A6. This revealed immunoreactivity only in the
mesencephalon, brain stem and spinal cord of sick mice
(Figure 5B). This was similarly observed in uninoculated
aged and sick M83 mice and in M83 mice inoculated
with brain extracts from sick mice or with fibrillar human
recombinant αS. These data suggest that recruitment of
the mouse protein occurs within the disease-associated αS
aggregates.
Results of αSD detection by immunohistochemistry,
Western blot and ELISA were then compared in mice
stereotaxically inoculated in the hippocampus or cerebel-
lum (second passage) (Figure 6). Immunohistochemistry
clearly showed a strong accumulation of pSer129 αS in
the caudal regions of the brain, such as the mesenceph-
alon, brain stem and in the spinal cord (Figure 6A and
D), but also showed αSD labeling in more frontal brain
regions such as the cerebral cortex (insets of Figure 6A
and Additional file 1: Figure S1A). The levels of αSD
were higher at the inoculation site, i.e. in the hippocam-
pus or at the deep cerebellar nuclei. In mice inoculated
Figure 2 Survival curves of M83 mice after intracerebral inoculations with brain extracts from sick M83 mice or with fibrillar
recombinant protein. The proportions of surviving mice following inoculations are shown. A. Second passage performed with 10 mg (red)
(n = 5), 2 mg (blue) (n = 8) and 0.4 mg (green) (n = 10) of brain equivalents, in comparison to a first passage performed with 2 mg (purple-dot)
(n = 8) of brain equivalents, or 10 μg of fibrillar recombinant αS. B. Second passages performed by stereotactic inoculations with 2 mg brain
equivalents from sick M83 mice into the hippocampus (red) (n = 5) or the cerebellum (green) (n = 4), in comparison to a first passage (purple-dot)
(n = 8) or a second passage using manual inoculation (blue). C. Second passages with 2 mg of spinal cord (red) (n = 9), cerebral cortex (n = 9)
(green) or spleen (dark blue) homogenates, in comparison to a first (purple-dot) (n = 8) or second passage (blue) (n = 8) performed with 2 mg of
total brain homogenates.
Bétemps et al. Acta Neuropathologica Communications 2014, 2:29 Page 5 of 14
http://www.actaneurocomms.org/content/2/1/29in the hippocampus, the accumulation of αSD was greater
in the inoculated hippocampus (I) than in the contro-
lateral side (C) (Figure 6B). αSD labeling was more import-
ant in the cerebral cortex following inoculation in the
hippocampus than in the cerebellum. In mice inoculated
in the cerebellum, no additional reactivity was ob-
served in the cerebellum sample when examined by
ELISA, in contrast to Western blot and immunohis-
tochemical analysis. Apart from this, Western blot,ELISA and immunohistochemistry provided very simi-
lar results, again emphasizing the stereotyped distribu-
tion of αSD more strongly accumulating in the caudal
parts of the brain of inoculated mice in this transgenic
mouse model [4,10].
Discussion
Our previous studies showed a striking acceleration of
synucleinopathy in a transgenic mouse model (M83)
Figure 3 Detection of αS by ELISA and Western blot in mice inoculated with different concentrations of whole brain homogenates. A.
Detection by ELISA of αSD with both LB509 and PSer129 antibody in sick M83 mice following inoculation with different concentrations of brain
homogenates (5, 1 or 0.2%, P2), and age-matched uninoculated mice. For the 5% brain homogenate, the signal is statistically lower than for the 1%
and 0.2% brain homogenates (**, p = 0.01). B. Western blot detection of αS with PSer129 antibody in the ultracentrifugation pellets in second
passage experiments at different concentrations (experiments 3–5). As observed in ELISA, lower levels of αSD were detected in the pellets
prepared from mice inoculated with the 5% brain homogenate, in comparison with most of the mice inoculated with the 1% and 0.2% brain
homogenates. In contrast, comparable levels of αS were detected by clone 42 antibody in crude brain homogenates and in the supernatants obtained
after ultracentrifugation. Comparable amounts of brain materials were loaded in each lane, as shown by an anti-β-actin antibody used as a loading
control. Ages at death of the mice are indicated below the graphs.
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mice were intra-cerebrally inoculated with brain ex-
tracts from old, sick M83 mice [14]. We have now con-
firmed these initial observations in experiments using
hemi-brain extracts from these mice that showed ac-
celerated disease after experimental challenge, thus
representing a “second passage” of the disease, as is
routinely performed to propagate prion strains inexperimental models. In these experiments, similar incu-
bation periods of the disease were observed after stereo-
tactic inoculation of the brain extracts into either the
cerebellum or hippocampus, although this latter brain re-
gion is acknowledged to be largely spared during normal
aging in this mouse line [4]. All but one mouse inoculated
with hemi-brain extracts in the cerebellum developed the
disease to a terminal stage well before the age of 8 months,
Figure 4 Detection of disease-associated α-synuclein (αSD) in different neuro-anatomical regions of M83 mice by ELISA and Western
blot. The following neuro-anatomical regions were sampled from sick M83 mice at first passage: OB: olfactive bulb, Cx: cerebral cortex, Hi:
hippocampus, St: striatum, Me: mesencephalon, Cb: cerebellum, BS: brain stem, SC: spinal cord. A-C. αSD was identified by Western blot with
PSer129 antibody (A), clone 42 (B) or LB509 (C) antibodies. In (D) the blots were revealed by an anti-β-actin antibody as a loading control. E-F.
ELISA results in these same neuro-anatomical regions were obtained with PSer129 or LB509 antibodies, in mice inoculated with brain homogenates
from sick M83 mice (P1) (n = 1, 4 repeats, mean ± SD) (E) or with fibrillar recombinant αS (n = 4, mean ± SD) (F). Molecular weight markers (in kDa) are
indicated on the left of panels A-D. Equal amounts of total proteins were used for equivalent loading on gel. *corresponds to a non specific band as
shown by the presence of a similar band in the absence of primary antibody and in αS-null mice (data not shown).
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[10]. Survival, in these second passage experiments, was
significantly longer when an extract prepared from the
cerebral cortex from a sick mouse was used, with 5/9 mice
surviving more than 8 months, although these mice devel-
oped the disease more rapidly than uninoculated M83
mice, which is consistent with the much lower levels of
αSD in this brain region (Additional file 1: Figure S1A). In
the cerebral cortex, αSD is however clearly detected in our
study by immunohistochemistry, although to a lesser ex-
tent compared to more caudal regions or the spinal cord,
consistent with other similar studies [4]. In the second
passage experiment performed by non stereotactic inocu-
lation (experiment 4), survival was significantly shorter
with 1% whole brain homogenate (from an inoculated
mouse) compared to that previously observed at first pas-
sage (from an old uninoculated mouse) (experiment 1) [5],
although insoluble pSer129 αSD levels in the inocula were
comparable (Additional file 1: Figure S1A); in this experi-
ment, a 20 μl volume at 1% of inoculum was inoculatedinstead of 2 μl at 10% in the stereotactic experiments
which showed a similar survival to that observed at first
passage. The precise mechanisms and molecular species
that contribute to the acceleration of the disease in such
experiments are far from being understood yet. A recent
study showed induction of αS pathology by intra-cerebral
inoculation of a non amyloidogenic form of recombinants
αS, raising the question of the contribution of neuroin-
flammation in such experiments [18]. In addition, the
presence of αS oligomers has been described in all exam-
ined brain regions of M83 mice, sharing similar basic bio-
chemical properties but showing subtle conformational
differences, those found in inclusion-bearing brain regions
significantly accelerating αS aggregation in vitro and caus-
ing primary cortical neuron degeneration [19]. The contri-
bution of these oligomers to the development of neuronal
dysfunction appears to be independent of their absolute
quantities and basic biochemical properties but is dictated
by the composition and conformation of the intermediates
as well as unrecognized brain-region-specific intrinsic
Figure 5 Species and time-specific detection of disease-associated α-synuclein (αSD) in selected neuro-anatomical regions. The
following neuro-anatomical regions were sampled from sick M83 mice: Me: mesencephalon, BS: brain stem, SC: spinal cord. A. ELISA results for 4
mice (1–4) inoculated (Inoc) with brain extract from sick M83 mice (P2) 12 weeks after the intra-cerebral inoculation, compared to an age-matched
uninoculated mouse (Uninoc). B. Detection of αSD of mouse origin in sick M83 mice using a mouse specific anti-αS antibody, D37A6, in an
uninoculated (Uninoc) sick mouse (276 days old) and in sick M83 mice inoculated with brain extracts from sick mice (P1) or with fibrillar human
recombinant αS (231 and 54 days post-inoculation respectively).
Bétemps et al. Acta Neuropathologica Communications 2014, 2:29 Page 8 of 14
http://www.actaneurocomms.org/content/2/1/29factors. Such molecular species could differ between
first and second passage experiments, as brain lesions
appeared more important after inoculation than during
normal aging [4].
We then used these experiments to obtain a detailed
characterization of αS aggregation in the brain. Western
blot analyses specifically revealed pSer129 αS in the insol-
uble fractions prepared by ultracentrifugation in the pres-
ence of sarkosyl, most abundantly in the mesencephalon,
brain stem and spinal cord. This disease-associated αS
protein (αSD) was typically undetected or only barely de-
tectable by this method in the more frontal brain regions,
such as the olfactory bulb, cerebral cortex, hippocampus
or striatum. The typical 4 band pattern, representing
monomeric or oligomeric ubiquitinated or not αS forms
[4,12,15], was similarly recognized by clone 42 antibody
and, to a much lesser extent, by LB509 antibody. SimilarαSD distribution was observed by immunohistochemis-
try using an antibody against pSer129 αS, which how-
ever also revealed specific immunolabeling of neurons
in more frontal parts of the brain such as the cerebral
cortex. In addition, when stereotaxically inoculated into
the hippocampus, αSD was also detected in this brain
region, more intensely in the inoculated side of the
brain than in the controlateral hippocampus. More in-
tense αSD labeling was also observed in the cerebellum
of mice that had been stereotactically injected in this
brain region. These data are consistent with previous
reports that αS aggregation was increased and/or earlier
around the sites of injection of brain homogenates from
sick mice [4,12]. The robust detection of αSD in caudal
brain regions that do not share direct innervations with
the injection site, similar to that observed during nor-
mal aging of M83 mice, further supports the hypothesis
Figure 6 Detection of disease-associated α-synuclein (αSD) in different neuroanatomical regions of M83 mice after stereotactic
inoculations in the hippocampus (A-C) or cerebellum (D-F) A, D. Detection of αS on sagittal brain sections by immunohistochemistry using
PSer129 antibody. (Scale bar, 1 mm. Insets are high magnifications of different areas). Arrows indicate the approximate sites of the stereotactic
inoculations. B, E. Detection of insoluble pSer129 αS by Western blot in selected neuro-anatomical regions. β-actin was used as loading control.
C, F. ELISA results with LB509 and PSer129 antibody in selected neuro-anatomical regions. Hi: hippocampus (Hi), C: contro-lateral side, I: inoculated
side, Cb: cerebellum, BS: brainstem, SC: spinal cord.
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propagation of αS pathology [4], this transfer being pos-
sibly more or less efficient depending on the molecular
species (monomers, oligomers or fibril) [20]. In a recent
study involving unilateral inoculation of αS preformed
fibrils (PFFs) in the hippocampus of transgenic human
P301S mutant tau mice, tau inclusions were reported
not only in all parts of the hippocampus, including re-
gions that were more rostral and caudal to the injection
site, but also in the contralateral hippocampus, and
even in the locus coeruleus, a brainstem structure dis-
tant from the injection site [21]. Whereas this tau aggre-
gation was triggered to a greater extent by one of two
aggregated forms of αS, both failed to induce substantial
αS pathology, in contrast with previous studies in wild-
type mice [11]. Interestingly, some recent studies of the
genesis of infectious prions from recombinant prion
proteins (PrP) suggested a new mechanism, designated
“deformed templating”, and postulated a required switch
from the protein folding pattern of recombinant PrP fibrils
to that of the disease-associated PrP to explain the long
silent stage before any disease can occur [22]. However,
our study in the M83 transgenic mouse model overex-
pressing A53T mutated human αS, still confirmed an ac-
celeration of the pathological process after intra-cerebral
inoculation of fibrillar recombinant human A53T αS,
similar to that observed following the inoculation of
brain extracts from sick M83 mice. Recent findings ob-
tained following the analysis of presymptomatic versus
symptomatic M83 mice suggested that the formation of
αS inclusions could be a relatively rapid and probably
synchronized process. Indeed, in mice with sparse or
moderate levels of αS inclusions, the distribution of
aggregates within affected areas of the neuroaxis was
diffuse and without clustering of inclusions, whereas
none of the presymptomatic mice exhibited abundant
αS inclusions [17].
The disease in M83 mice was further characterized by
setting up an ELISA test that has been shown to specif-
ically detect αSD directly from mouse brain homoge-
nates. Indeed, ELISA analyses of brain homogenates,
prepared from whole brains without any concentration
step, readily enabled sick mice to be distinguished from
healthy M83 mice, although some variability in αSD levels
was apparent between different mice from the same ex-
perimental group. In a second passage experiment with
different inocula concentrations, mice inoculated with
10 mg of brain tissue equivalents had significantly lower
αSD levels than those inoculated with only 2 or 0.4 mg.
The biological significance of this variability, if any, re-
mains unexplained, but the ELISA results were tightly
correlated with the Western blot analyses of insoluble
pSer129 αS. Although such experiments should still be
repeated with larger number of animals, it could suggestsubtle differences in αS biochemical properties that could
be more difficult to extract when higher amounts of aggre-
gated αS have been inoculated. The possible variable ef-
fects of different quantities of aggregated αS inoculated
on the features of αS aggregates ultimately found in the
brain of recipients have been considered in a recent
study, emphasizing that different lesions have been ob-
served in different studies involving inoculations of dif-
ferent quantities of aggregated recombinant αS [23].
Alternatively, considering that mice inoculated with the
higher αSD concentrations have also received higher
amounts of non-αS brain components in our experi-
ments, it should be noticed that it has been suggested
that, beside “prion-like” protein self templating, neuro-
inflammation could be an important event in such ex-
periments, thus possibly modifying the course of the
disease according to the inoculation conditions [18,23],
giving shorter survival despite lower αSD levels in the
brain of M83 mice. In agreement with Western blot
analyses, immunoreactivity was specifically identified
in the mesencephalon, brain stem and spinal cord by
ELISA, but was not detected in the olfactory bulb, cere-
bral cortex or striatum. Similarly, it was not detected in
the hippocampus, except in mice stereotaxically inocu-
lated in this brain region. Although the analytical sensitiv-
ity of the ELISA test on brain homogenates appeared to
be ~ 20× more sensitive than our previously described
Western blot method on brain extracts prepared by ultra-
centrifugation in the presence of sarkozyl [5], it remained
lower at this stage than that of immunohistochemical de-
tection, which also allows the detection of αSD in individ-
ual cells in the frontal brain regions. This is consistent
with our observation of accelerated disease following
intra-cerebral inoculation of a brain extract prepared
from the cerebral cortex from a sick M83 mouse, al-
though these mice showed a longer survival than those
inoculated with a spinal cord homogenate. These differ-
ences in sensitivity were also apparent in ELISA ana-
lyses of mice 8 or 12 weeks after their inoculation with
brain extracts from sick M83, which were positive at
12 weeks, but negative at 8 weeks. In contrast, data pre-
viously obtained from similar experiments in this same
M83 model using immunohistochemistry, showed that
αSD could be detected as early as 30 days after experimen-
tal challenge [4]. All together, our data show clear ELISA
differentiation between sick and healthy mice, and be-
tween brain regions differently affected by the pathological
process, thereby demonstrating that the ELISA approach
specifically recognizes disease-associated αS.
Importantly, similar results were obtained by this
ELISA test, not only with a monoclonal antibody spe-
cifically recognizing pSer129 αSD, but also with several
other antibodies. It is however remarkable that we failed
to detect any immunoreactivity by ELISA analysis of sick
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region of αS (91–96) [24,25]. This suggests that the rec-
ognized epitope could be cryptic under our ELISA con-
ditions while it is exposed in samples denatured for
Western blot detection. This agrees with our recent
structural investigations which revealed that αS residues
91–93 or 91–97 are involved in beta-sheet structures
within aggregated αS [26]. Only very slight immunoreactiv-
ity was observed with an antibody against the N-terminal
end (2–14) of the protein, Syn-514, that is reported to
recognize conformational variants of αS enhanced by the
presence of the double mutation E46K/A53T [15,27].
However much higher immunoreactivity was detected
with several antibodies directed against the C-terminal
part (115–140) of αS: these included LB509, produced
against Lewy bodies (amino acid 115–122) and specific-
ally recognizing the human protein, and 8A5 reported
to be produced against 129–140 amino-acid and react-
ing with αS species in Lewy bodies [28]. Interestingly,
high immunoreactivity was also observed with the 4D6
antibody, that was recently described to specifically
recognize the 124–134 region of the non phosphory-
lated form of αS at serine residue 129 [29]. This in-
dicates that non phosphorylated αS could also be
significantly involved in the aggregation process in this
model, even though recent studies have suggested that
this phosphorylation occurs in the brain after Lewy bod-
ies formation and more importantly at their periphery
[30,31]. Neuronal inclusions not reacting with pSer129
antibodies by immunohistochemistry have already been
reported with the M83 model [15], as well as a dramatic
increase of total αS in the brain between the ages of 2
and 6 months [32]. In human PD patients, a recent study
in which αS levels were assessed by ELISA in the plasma
up to 20 years after the initial symptoms, showed a steady
increase of total αS as the disease progressed, whereas the
pSer129 αS levels remained relatively constant, suggesting
that disease progression could be monitored by measuring
non phosphorylated αS [30].
Finally, we were able to use the ELISA approach to
demonstrate immunoreactivity with an antibody specif-
ically recognizing mouse αS (amino-acids 103–110) from
brain homogenates that also reacted with the antibody
against pSer 129 αS or with the LB509 antibody that
only recognizes human αS. This immunoreactivity with
the anti-mouse antibody, although much smaller than
that observed with the two other antibodies, was quite
consistent. This result is in line with previous observa-
tions in similar experiments involving M83 mice, where
it was concluded that murine αS might be recruited dur-
ing human αS aggregation in M83 mice [4]. More re-
cently, aggregation of murine αS was also reported
following intra-cerebral inoculation in wild-type mice,
not only of fibrillar recombinant mouse αS [11], butalso of fibrillar recombinant human αS or brain ex-
tracts from human patients with dementia with Lewy
bodies [12].
Conclusions
Our data confirm the consistent acceleration of disease
following intra-cerebral inoculation of brain extracts
from sick M83 mice or fibrillar recombinant αS, sug-
gesting that disease propagation involves a prion-like
mechanism, and further indicating that this can also be
observed in serial passages, as routinely performed in
experimental models of prion diseases. Detailed αS mo-
lecular analyses using an ELISA approach revealed
striking differences in immunoreactivity with different
antibodies in sick mice, questioning their possible rela-
tionship with conformational differences between the
disease-associated αS and its normal counterpart. These
data will however provide useful tools for further ex-




For this study, we used a transgenic mouse line (M83),
that over-expresses the human A53T αS (B6; C3H-Tg
[SNCA]83Vle/J, The Jackson laboratory, Bar Harbor, ME)
[10] and spontaneously develop a dramatic motor pheno-
type between 8 and 22 months of age. At the end of their
life, M83 mice present characteristic clinical symptoms
including weight loss, reduced ambulation, severe motor
impairment, prostration, and partial hind limb paralysis
with overall stiffness of the hind legs and tail. The mice
become unable to get up when placed on their backs.
Animal experiments performed in this study are sum-
marized in Table 1.
For non stereotactic experiments, 6–9 week-old homo-
zygous M83 mice were anesthetized by 3% isoflurane
inhalation and inoculated intracerebrally in the striato-
cortical area with i) 20 μl brain homogenates (0.2, 1 or
5% wt/vol in glucose 5%) obtained from half brains of
sick M83 mice as previously described [5] or ii) recom-
binant fibrillar (10 μg per mouse) human A53T αS
[26]. In selected experiments, homogenates were simi-
larly prepared from the spinal cord, cerebral cortex or
spleen from a same sick M83 mouse. In the case of
stereotactic experiments, 6 week-old homozygous M83
mice were anesthetized with a mixture of 20 mg/kg
xylazine/ 60 mg/kg ketamine and inoculated intracere-
brally with 2 μl brain homogenates (10% in glucose 5%)
in the left hippocampus (anterior-posterior (AP):-2,92;
medial-lateral (ML): +3; dorsal-ventral (DV):-3.5), or in
the cerebellum (AP: −5.8, ML: +2.25, DV: 3) from the
bregma. Controls included uninoculated and asymptom-
atic M83 mice between 2 and 7 months, sick old M83
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C57BL/6S (B6 αS-null) mice, presenting a deletion of the
α-syn locus (Harlan, Gannat, France) [16].
The animals were housed and cared for in our approved
experimental facilities (n° B 69 387 0801), in accordance
with the EC Directive 86/609/EEC and with the Cometh,
the National Committee for Ethical Experimentation on
Animals (protocol n° 11–0043).Extractions of α -synuclein
For biochemical analysis, αS extractions were performed
as previously described [5,14]. Briefly, about 20% brain
homogenates were prepared in high salt buffer (50 mM
Tris–HCl, pH 7.5, 750 mM NaCl, 5 mM EDTA, 1 mM
DTT, 1% phosphatase and protease inhibitor cocktails)
from half of a brain, using a mechanical homogenizer
(grinding balls, Fast prep-FTI20, Thermo). In some of
the experiments, dissection was performed immediately
after euthanasia, and depending on the quantity of avail-
able tissue from each part of the dissected brain or
spinal cord, 5, 10 or 20% (wt/vol) homogenates were ob-
tained, on ice with a Dounce borosilicate glass grinder.
After centrifugation at 1,000 × g (5 min at +4°C), the
supernatants were recovered for ELISA analysis and
diluted, depending on the initial concentrations of the
homogenates. For analysis of the insoluble αS fraction
in Western blot, we used about 200 μl of the super-
natants. The supernatants were incubated on ice for
15 min in N-lauroylsarcosyl at a final concentration of
10% before being ultracentrifuged at 465,000 × g
(1 hour at +4°C) over a 10% sucrose cushion. The pel-
lets (detergent-insoluble/SDS-soluble fraction) were
resuspended in 40 μl of TD4215 denaturing buffer (4%
SDS, 2% β-mercaptoethanol, 192 mM glycine, 25 mM
Tris, 5% sucrose).Table 2 Antibodies used in this study
Antibodies Epitopic specificity Typ
LB509 (human α-syn) 115-122 Mouse mo
4D6 (α-syn) 124–134 Mouse mo
clone42 (α-syn) 91–96 Mouse mo
syn514 (α-syn) 2–12 Mouse mo
8A5 (α-syn) 129–140 Mouse mo
D37A6 (mouse α-syn) 103–110 Rabbit pol
phosphorylated α-syn* PSer129 Rabbit pol
EP1536Y (phosphorylated α-syn)** PSer129 Rabbit mo
EP1537Y (β-syn) Rabbit mo
Actin Mouse mo
All antibodies were used in ELISA with polyclonal anti α-syn antibody (Millipore ref
*Antibody used in ELISA with monoclonal anti α-syn clone 42 as capture.
**Antibody used in Western blot and immunochemistry.
E: ELISA, WB: Western blot.Western blot analysis
After heat denaturation (5 min at 100°C), the proteins
were separated by electrophoresis using 12% SDS-
polyacrylamide gels before being electroblotted onto
polyvinylidene fluoride membranes (BioRad, Marnes La
Coquette, France). αS was probed with either mouse
monoclonal antibody (mAb) clone 42 against αS (BD
Transduction Laboratories), LB509 against human αS
(ref ab27766), rabbit mAb against pSer129 αS (ref
ab51253; Abcam, Cambridge, UK) or rabbit polyclonal
antibody (pAb) against pSer129 αS (ref ab59264; Abcam,
Cambridge, UK) (Table 2). Anti-actin mAb (ref ab8226;
Abcam, Cambridge, UK) and anti-βsyn (ref ab76111;
Abcam, Cambrigde, UK) were used as controls. The
membranes were then incubated with horseradish per-
oxidase conjugated goat anti-mouse (ref 32460; Thermo)
or anti-rabbit (ref 32430; Thermo) Ig secondary anti-
bodies (1:1000). The immunocomplexes were visualized
with chemiluminescent reagents (Supersignal WestDura,
ref 34076, Thermo), followed by exposure on Biomax
MR Kodak films, or CL-Exposure films, and by analysis
using the Versa Doc system and Quantity One software
(both from BioRad).
Immunohistochemistry
Immunohistochemistry was performed on buffered 10%
formalin-fixed samples as previously described, including
pretreatments with boiling 5 min in 0.1 mol/L of citrate
buffer (pH 6.2) using a microwave oven and 20 min
immersion in a 3 mol/L guanidine isothiocyanate solu-
tion [5,14]. The primary antibody used was rabbit mAb
against pSer129 αS (ref ab51253; Abcam, Cambridge,
UK) (Table 2). The secondary antibody was HRP-labeled
anti-rabbit Ig antibody (1:200) (ref 401004; Southern
Biotech). Antibody binding was detected using the
avidin-biotin complex system (Vector Laboratories,e Source Dilution (ELISA/WB/IHC)
noclonal Abcam (ref ab27766) 1/2000E -1/1000WB
noclonal Abcam (ref ab1903) 1/2000E
noclonal BD Biosciences (ref 610787) 1/2000E/WB
noclonal Abcam (ref ab24717) 1/500E
noclonal Provided by Dr. Anderson 1/2000E
yclonal Cell Signaling (ref 4179) 1/1000E
yclonal Abcam (ref ab59264) 1/3000E -1/1000WB
noclonal Abcam (ref ab51253) 1/1000WB-1/300IHC
noclonal Abcam (ref ab76111) 1/5000WB
noclonal Abcam (ref ab8226) 1/2000WB
AB5038P) as capture, unless mentioned.
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aminobenzidine intensified with nickel chloride.
ELISA
The αS levels in brain extracts were measured using a
sandwich ELISA. Plates (MaxiSorp™, Thermo Scientific
Nunc) were coated with capture antibodies, either 0.01 ng/
ml anti αS rabbit polyclonal (Millipore, ref AB5038P) or
monoclonal clone 42 antibody (BD Biosciences, ref 610787)
in 50 mM Na2CO3/NaHCO3 (pH9.6) with 100 μl per well
at 4°C overnight. Plates were washed 5 times in phosphate-
buffered saline with 0.05% Tween20 (PBST). Superblock
T20 PBS blocking buffer (Pierce) was then added for 1 h at
room temperature (RT) with shaking at 150 rpm. The
plates were again washed 5 times in PBSTand the brain ho-
mogenates (dilution 1:100 of the 20% homogenates in
PBST BSA 1%) and standards (human α-syn recombinant-
Sigma) were incubated at 25°C for 2 h with shaking. After
washing 5 times with PBST, captured αS protein was de-
tected by different antibodies against αS (Table 2). The
plates were washed 5 times in PBST and either anti-
mouse (ref 1010–05, Southern Biotech) or anti-rabbit
(ref 4010–05, Southern Biotech) IgG HRP conjugates
was added at 1:8000 dilution in PBST BSA 1% for 1 h
at RT. After washing the plates 5 times with PBST,
100 μl of 3,3′,5,5′-tetramethylbenzidine (TMB) solu-
tion (ref T0440, Sigma) was added to each well and in-
cubated for 15 min with shaking. The reaction was
stopped with 100 μl of 1 N HCl, and the absorbance
was measured at 450 nm with the microplate reader
Model 680 (Biorad). For data analysis, the OD value
obtained in the well with all the reagents except the
sample (Blank well) was subtracted from the OD value
of each analyzed sample.Statistical analysis
The incubation period is the time from the day of inocu-
lation until death (d.p.i.). The distributions of incubation
period between groups were compared after fitting the
data with Cox regression models. Tests and diagnostics
of the proportional hazards assumption of the Cox models
were based on weighted residuals. When comparisons
were required between several groups, Tukey’s multiple
tests method was applied.
Mixed-effects regressions were used to model OD. A
mixed effect was used to reflect the variability of the
repetitions for a given mouse. Given that the residuals of
the models gave a clear indication of heteroscedasticity,
the variance matrix was appropriately parameterized.
Validation of the model was based on examination of
the residuals. Analyses were done with R version 1.15.1
and the packages nlme and survival. A significance
threshold of P = 0.05 was used for all experiments.Recombinant αS purification and assembly
Recombinant human A53T αS was expressed and purified
as described previously [33]. Soluble A53T αS was incu-
bated in buffer A (50 mM Tris–HCl, pH 7.5, 150 mM
KCl) at 37°C under continuous shaking in an Eppendorf
Thermomixer set at 600 r.p.m. Assembly was monitored
continuously using Thioflavin T binding and the nature of
the fibrillar assemblies was assessed by electron micros-
copy as described [34].Additional file
Additional file 1: Figure S1. Western blot detection of αS in
asymptomatic versus symptomatic M83 mice and in the inocula used in
the study. A. Comparison of levels of αSD in the different inocula used for
experiments 1 to 10 (Table 1). αSD was detected in the
ultracentrifugation pellets used as inocula for first passage (experiment 1)
(P1) or for second passage, from half-brain (P2) (experiments 3–7) or
from different areas including spinal cord (SC), cortex (Cx), or spleen
(Spl) (experiments 8–10) using PSer129 antibody. B.Western blot detection
of αS in 20% crude brain homogenates of symptomatic or asymptomatic
M83 mice, in comparison to the pellets and supernatants obtained after
utltracentrifugation. pSer129 αS was detected only in the pellets of
symptomatic mice using PSer129 αS antibody. C. Detection of αS in
20% crude brain homogenates was comparable in asymptomatic and
symptomatic M83 mice with both clone 42 and LB509 antibodies. No
αS was observed in B6 αS-null mice with the same antibodies, and in
B6C3H mice also with LB509 antibody that recognizes only human αS.
All mice except B6 αS-null mice presented αS detected by D37A6
antibody, specifically directed against murine αS. As a control,
β-synuclein was detected in all the mice with the β-synuclein specific
antibody EP1537Y [35]. Molecular weight markers (in kDa) are indicated on
the left of panels A-B. The blots were also revealed by an anti-β-actin
antibody as a loading control.
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